Third Rock Ventures news from FierceBioResearcher
NewsVC firm looks to early-stage research projects
Third Rock Ventures recently unveiled a $378 million life sciences fund which it says will concentrate on early-stage drug discovery--linking academic research to biotech companies. In an interview Read more...
| Press ReleasesPRESS RELEASE: Third Rock Ventures Debuts with $378 Million Fund in Life Sciences Third Rock Ventures Debuts with $378 Million Fund in Life Sciences Partners are Former Biotech Executives who Bring Operating Experience to Identify and Launch Companies at Early Stages of Formation Read more... |
Get more Third Rock Ventures coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets